Given Imaging Announces Results of 2013 Annual Shareholders' Meeting

Given Imaging Announces Results of 2013 Annual Shareholders' Meeting

YOQNEAM, Israel, July 31, 2013 (GLOBE NEWSWIRE) -- Given Imaging Ltd.
(Nasdaq:GIVN) today announced the results of its annual shareholders' meeting
which was held today in Yoqneam, Israel. A total of 21,995,585 shares, or
approximately 70%, of the total number of shares entitled to vote at the
meeting, were represented, and the two proposed resolutions were approved.

The following resolutions were approved:

1.Election of Mr. Lior Hannes as a director, and the re-election of Israel
    Makov (Chairman of the Board of Directors), Arie Mientkavich, Doron
    Birger, Nachum (Homi) Shamir, Prof. Anat Loewenstein, Ari Bronshtein, and
    Stanley Stern and as directors of the company until the next Annual
    General Meeting of Shareholders;
2.Re-appointment of Somekh Chaikin, a member of KPMG International, as the
    Company's independent auditors until the Company's next Annual General
    Meeting of Shareholders and authorization of the Company's Audit Committee
    and Board of Directors to determine their remuneration.

The Board of Directors wishes to thank shareholders for participating and
voting at this annual general meeting.

About Given Imaging Ltd.

Since pioneering the field of capsule endoscopy in 2001, Given Imaging has
become a world leader in GI medical devices, offering health care providers a
range of innovative options for visualizing, diagnosing and monitoring the
digestive system. The company offers a broad product portfolio including
PillCam® capsule endoscope for the small bowel, esophagus and colon. The
company also offers industry-leading GI functional diagnostic solutions
including ManoScan® high-resolution manometry, Bravo® capsule-based pH
monitoring, Digitrapper® pH-Z, and the SmartPill® GI monitoring systems. Given
Imaging is committed to delivering breakthrough innovations to the GI
community and supporting its ongoing clinical needs. Given Imaging's
headquarters are located in Yoqneam, Israel, with operating subsidiaries in
the United States, Germany, France, Japan, Australia, Vietnam, Hong Kong and
Brazil. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not limited to,
projections about our business and our future revenues, expenses and
profitability. Forward-looking statements may be, but are not necessarily,
identified by the use of forward-looking terminology such as "may,"
"anticipates," "estimates," "expects," "intends," "plans," "believes," and
words and terms of similar substance. Forward-looking statements involve known
and unknown risks, uncertainties and other factors which may cause the actual
events, results, performance, circumstances or achievements of the Company to
be materially different from any future events, results, performance,
circumstances or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements include statements relating to the
Company exploring strategic alternatives and considering possible strategic
transactions involving the Company. Factors that could cause actual events,
results, performance, circumstances or achievements to differ from such
forward-looking statements include, but are not limited to, the following: (1)
our ability to develop and bring to market new products, (2) our ability to
successfully complete any necessary or required clinical studies with our
products, (3) our ability to receive regulatory clearance or approval to
market our products or changes in regulatory environment, (4) our success in
implementing our sales, marketing and manufacturing plans, (5) the level of
adoption of our products by medical practitioners, (6) the emergence of other
products that may make our products obsolete, (7) lack of an appropriate bowel
preparation materials to be used with our PillCam COLON capsule, (8)
protection and validity of patents and other intellectual property rights, (9)
the impact of currency exchange rates, (10) the effect of competition by other
companies, (11) the outcome of significant litigation, (12) our ability to
obtain reimbursement for our product from government and commercial payors,
(13) quarterly variations in operating results, (14) the possibility of armed
conflict or civil or military unrest in Israel, (15) the impact of global
economic conditions, (16) our ability to successfully integrate acquired
businesses, (17) changes and reforms in applicable healthcare laws and
regulations, (18) quality issues and adverse events related to our products,
such as capsule retention, aspiration and failure to attach or detach,
bleeding or perforation that could require us to recall products and impact
our sales and net income, and (19) other risks and factors disclosed in our
filings with the U.S. Securities and Exchange Commission, including, but not
limited to, risks and factors identified under such headings as "Risk
Factors," "Cautionary Language Regarding Forward-Looking Statements" and
"Operating Results and Financial Review and Prospects" in the Company's Annual
Report on Form 20-F for the year ended December 31, 2012. You are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Except to the extent expressly
required under applicable law, the Company undertakes no obligation to release
publicly any revisions to any forward-looking statements, to report events or
to report the occurrence of unanticipated events.

CONTACT: Fern Lazar/David Carey
         Lazar Partners Ltd.
         212 867 1768
         Israel Investor Contact:
         Nava Ladin
         Gelbart Kahana Investor Relations
Press spacebar to pause and continue. Press esc to stop.